BioSpace News Archive

VIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC).

Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting taking place July 25-29 in Toronto.

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta (“PI3Kδ”) inhibitor.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 third quarter ended June 30, 2022, before the opening of the market on Aug. 5, 2022.

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the first patient has been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating the administration of THIO, in sequence with cemiplimab, in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022.

Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference.

Alzamend Neuro, Inc. today announced that it has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (the “FDA”).

Lucid Diagnostics Inc. today announced that Dr. Lishan Aklog, Chairman and CEO, has been invited to present at the CG 42nd Annual Growth Conference taking place at the InterContinental Boston from August 8 – 11.